147 related articles for article (PubMed ID: 35341390)
21. Association of Uveal Melanoma Metastatic Rate With Stochastic Mutation Rate and Type of Mutation.
Szalai E; Jiang Y; van Poppelen NM; Jager MJ; de Klein A; Kilic E; Grossniklaus HE
JAMA Ophthalmol; 2018 Oct; 136(10):1115-1120. PubMed ID: 30073324
[TBL] [Abstract][Full Text] [Related]
22. BRAF V600E-dependent role of autophagy in uveal melanoma.
Zhao Y; Wang W; Min I; Wyrwas B; Moore M; Zarnegar R; Fahey TJ
J Cancer Res Clin Oncol; 2017 Mar; 143(3):447-455. PubMed ID: 27928645
[TBL] [Abstract][Full Text] [Related]
23. Expression of BAP1 and ATM proteins: Association with AJCC tumor category in uveal melanoma.
Jha J; Singh MK; Singh L; Pushker N; Bajaj MS; Sen S; Kashyap S
Ann Diagn Pathol; 2020 Feb; 44():151432. PubMed ID: 31864162
[TBL] [Abstract][Full Text] [Related]
24. Expression of haematogenous and lymphogenous chemokine receptors and their ligands on uveal melanoma in association with liver metastasis.
Dobner BC; Riechardt AI; Joussen AM; Englert S; Bechrakis NE
Acta Ophthalmol; 2012 Dec; 90(8):e638-44. PubMed ID: 23164171
[TBL] [Abstract][Full Text] [Related]
25. BAP1 Syndrome - Predisposition to Malignant Mesothelioma, Skin and Uveal Melanoma, Renal and Other Cancers.
Foretová L; Navrátilová M; Svoboda M; Házová J; Vašíčková P; Sťahlová EH; Fabian P; Schneiderová M; Macháčková E
Klin Onkol; 2019; 32(Supplementum2):118-122. PubMed ID: 31409087
[TBL] [Abstract][Full Text] [Related]
26. BAP1 Germline Mutations in Finnish Patients with Uveal Melanoma.
Turunen JA; Markkinen S; Wilska R; Saarinen S; Raivio V; Täll M; Lehesjoki AE; Kivelä TT
Ophthalmology; 2016 May; 123(5):1112-7. PubMed ID: 26876698
[TBL] [Abstract][Full Text] [Related]
27. Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing.
Kalirai H; Dodson A; Faqir S; Damato BE; Coupland SE
Br J Cancer; 2014 Sep; 111(7):1373-80. PubMed ID: 25058347
[TBL] [Abstract][Full Text] [Related]
28. Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma.
Kim JH; Shin SJ; Heo SJ; Choe EA; Kim CG; Jung M; Keum KC; Yoon JS; Lee SC; Shin SJ
Cancer Res Treat; 2018 Oct; 50(4):1238-1251. PubMed ID: 29281872
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
[TBL] [Abstract][Full Text] [Related]
30. Uveal Melanoma in BAP1 Tumor Predisposition Syndrome: Estimation of Risk.
Singh N; Singh R; Bowen RC; Abdel-Rahman MH; Singh AD
Am J Ophthalmol; 2021 Apr; 224():172-177. PubMed ID: 33316260
[TBL] [Abstract][Full Text] [Related]
31. Correlation of Immunocytochemistry of BRCA1-associated Protein-1 (BAP1) With Other Prognostic Markers in Uveal Melanoma.
Glasgow BJ; McCannel TA
Am J Ophthalmol; 2018 May; 189():122-126. PubMed ID: 29530782
[TBL] [Abstract][Full Text] [Related]
32. Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes.
Decatur CL; Ong E; Garg N; Anbunathan H; Bowcock AM; Field MG; Harbour JW
JAMA Ophthalmol; 2016 Jul; 134(7):728-33. PubMed ID: 27123562
[TBL] [Abstract][Full Text] [Related]
33. Transposase mapping identifies the genomic targets of BAP1 in uveal melanoma.
Yen M; Qi Z; Chen X; Cooper JA; Mitra RD; Onken MD
BMC Med Genomics; 2018 Nov; 11(1):97. PubMed ID: 30400891
[TBL] [Abstract][Full Text] [Related]
34. Differential expression of chemokine receptors on uveal melanoma cells and their metastases.
Li H; Alizadeh H; Niederkorn JY
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):636-43. PubMed ID: 18235009
[TBL] [Abstract][Full Text] [Related]
35. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M
Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967
[TBL] [Abstract][Full Text] [Related]
36. Metastatic disease in uveal melanoma: importance of a genetic profile?
Van Beek JG; Koopmans AE; Vaarwater J; Verdijk RM; de Klein A; Naus NC; Kiliç E
Melanoma Res; 2015 Oct; 25(5):447-9. PubMed ID: 26086698
[TBL] [Abstract][Full Text] [Related]
37. BAP1 germline mutation in two first grade family members with uveal melanoma.
Maerker DA; Zeschnigk M; Nelles J; Lohmann DR; Worm K; Bosserhoff AK; Krupar R; Jägle H
Br J Ophthalmol; 2014 Feb; 98(2):224-7. PubMed ID: 24187051
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
Schaper-Gerhardt K; Okoye S; Herbst R; Ulrich J; Terheyden P; Pföhler C; Utikal JS; Kreuter A; Mohr P; Dippel E; Satzger I; Sucker A; Schadendorf D; Ugurel S; Gutzmer R
Eur J Cancer; 2018 Jan; 88():67-76. PubMed ID: 29195116
[TBL] [Abstract][Full Text] [Related]
39. PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro.
Yang W; Chen PW; Li H; Alizadeh H; Niederkorn JY
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2518-25. PubMed ID: 18296654
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Factor Utility of BAP1 Immunohistochemistry in Uveal Melanoma: A Single Center Study in Spain.
Tabuenca Del Barrio L; Nova-Camacho LM; Zubicoa Enériz A; Martínez de Espronceda Ezquerro I; Córdoba Iturriagagoitia A; Borque Rodríguez-Maimón E; García-Layana A
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
